Advertisement

Topics

Bayer Enters Global Collaboration With Loxo For Larotrectinib, LOXO-195

07:35 EST 14 Nov 2017 | FinanzNachrichten

LEVERKUSEN (dpa-AFX) - Loxo Oncology, Inc. (LOXO) announced a global collaboration with Bayer to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology's franchise of TRK inhibitors f...

Original Article: Bayer Enters Global Collaboration With Loxo For Larotrectinib, LOXO-195

NEXT ARTICLE

More From BioPortfolio on "Bayer Enters Global Collaboration With Loxo For Larotrectinib, LOXO-195"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...